HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House Appropriators' Report Tracks With FDA Concern About CBD Supplements

Executive Summary

House Appropriators expect FDA to assert commitment to identifying lawful regulatory pathways for CBD food and supplements if those pathways are consistent with protection of public health. Committee also expresses concern over proliferation of CBD supplements and foods in violation of FDA regulations.

You may also be interested in...

FDA Appropriation Targets $100,000 To Find Safe CBD Level In Supplements

Rep. McNerneny's amendment calls for process that would follow steps FDA used in exercising enforcement discretion on natural products that contain levels of an approved drug ingredient, with red yeast rice most notable. But critics of FDA's VMS industry oversight don't see McNerney's amendment as effective not only for strengthening FDA's overall regulation but also for solving its CBD problem.

FDA Cosmetics Funding ‘Inadequate’ – Appropriators Propose $4m Increase

Proposing $4m bump in FY 2020 for Office of Cosmetics and Colors, House appropriators are "concerned that FDA’s current authority and resources to oversee cosmetics and personal care products are inadequate to properly ensure the safety of cosmetics products.”

Acetaminophen Dose Labeling, More Sunscreen Information Needed, House Appropriators Tell FDA

Appropriators are "concerned that the lack of dosing information" on OTC drugs for children ages six months to 2 years "may lead to dosing errors, adverse events and inadequate treatment of fever and pain.” They also ask USDA about fraud in its National Organic Program.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts